E
Erin Trachet
Researcher at Pfizer
Publications - 9
Citations - 1431
Erin Trachet is an academic researcher from Pfizer. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 4, co-authored 6 publications receiving 1258 citations.
Papers
More filters
Journal Article
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
David W. Fry,Patricia J. Harvey,Paul R. Keller,William Elliott,Maryanne Meade,Erin Trachet,Mudher Albassam,Xianxian Zheng,Wilbur R. Leopold,Nancy Pryer,Peter L. Toogood +10 more
TL;DR: Results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors.
Journal ArticleDOI
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Gonzales Andrea,Kenneth E. Hook,Irene W. Althaus,Paul A. Ellis,Erin Trachet,Amy M. Delaney,Patricia J. Harvey,Teresa Ellis,Danielle M. Amato,James M. Nelson,David W. Fry,Tong Zhu,Cho-Ming Loi,Stephen Fakhoury,Kevin Matthew Schlosser,Karen Elaine Sexton,R. Thomas Winters,Jessica Elizabeth Reed,Alex J. Bridges,Daniel J. Lettiere,Deborah A. Baker,Jianxin Yang,Helen Lee,Haile Tecle,Patrick W. Vincent +24 more
TL;DR: Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in ErbB1 (EGFR) associated with resistance to gefitinib and erlotinib.
Journal ArticleDOI
Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
Jeff B. Smaill,Gonzales Andrea,Julie Ann Spicer,Helen Tsenwhei Lee,Jessica Elizabeth Reed,Karen Elaine Sexton,Irene W. Althaus,Tong Zhu,Shannon Leigh Black,Adrian Blaser,William A. Denny,Paul A. Ellis,Stephen Fakhoury,Patricia J. Harvey,Ken Hook,Florence O. McCarthy,Brian D. Palmer,Freddy Rivault,Kevin Matthew Schlosser,Teresa Ellis,Andrew M. Thompson,Erin Trachet,R. Thomas Winters,Haile Tecle,Alexander James Bridges +24 more
TL;DR: Pharmacokinetic comparison of compounds 54 and 71 across three species selected compound 54 as the preferred candidate and has been assigned the nomenclature of dacomitinib and is currently under clinical evaluation.
Book ChapterDOI
Preclinical Models of Tumor Growth and Response
Patrick McConville,William Elliott,Alicia R. Kreger,Richard Lister,Jonathan B. Moody,Erin Trachet,Frank Urban,W. R. Leopold +7 more
TL;DR: With recent advances in preclinical imaging technologies, these models are also proving useful in the development and testing of new imaging techniques and contrast agents and are also being used to optimize and validate clinical imaging strategies.
Proceedings ArticleDOI
Abstract C232: ALB‐109564, a novel tubulin inhibitor with improved efficacy over vinorelbine, is better tolerated when dosed iv versus ip, leading to improved activity in human tumor xenograft studies
Mark A. Wolf,Randall K. Johnson,Deijian Xie,Anna Avrutskaya,Robert J. Mullin,Beverly Godfrey,Mary Ann Mead,Erin Trachet,Wilbur R. Leopold,Peter R. Guzzo,Scott Ian L +10 more
TL;DR: Preclinical evaluation of tubulin inhibitor ALB‐109564 (12′‐methylthiovinblastine dihydrochloride) demonstrated in vivo oncolytic activity against several human tumor cell types in xenograft models greater than that seen with vinorelbine.